Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.210
0.00 (0.00%)
Mar 2, 2026, 2:22 PM GMT
-23.64%
Market Cap 4.51M
Revenue (ttm) n/a
Net Income (ttm) -2.01M
Shares Out 2.15B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,802,915
Average Volume 7,409,034
Open 0.200
Previous Close 0.210
Day's Range 0.200 - 0.210
52-Week Range 0.175 - 0.300
Beta 1.47
RSI 46.08
Earnings Date Dec 3, 2025

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.